University of Los Andes (Colombia)

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

Retrieved on: 
Jeudi, novembre 9, 2023
University of Los Andes (Colombia), IPO, Biogen, Therapy, Tajikistan State University of Law, Business, & Politics, Tree, Doctor of Philosophy, MBA, Engineering, HEC Paris, Central Executive Committee (PAP), Politics, Growth, Trinity College, Medicine, Paris, Executive Committee, Business, Senior, University of Hamburg, Ethicon, University, Trinity College Dublin, Sanofi, International communication, La Jolla Institute for Immunology, Immunology, Management, Bayer, Merck

BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, today announced the appointment of three new members to the Executive Team.

Key Points: 
  • "Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships.
  • We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy.
  • Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics.
  • For further information on the Executive Committee, visit www.treefrog.fr

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

Retrieved on: 
Jeudi, novembre 9, 2023
University of Los Andes (Colombia), IPO, Biogen, Therapy, Tajikistan State University of Law, Business, & Politics, Tree, Doctor of Philosophy, MBA, Engineering, HEC Paris, Central Executive Committee (PAP), Politics, Growth, Trinity College, Medicine, Paris, Executive Committee, Business, Senior, University of Hamburg, Ethicon, University, Trinity College Dublin, Sanofi, International communication, La Jolla Institute for Immunology, Immunology, Management, Bayer, Merck

BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, today announced the appointment of three new members to the Executive Team.

Key Points: 
  • "Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships.
  • We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy.
  • Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics.
  • For further information on the Executive Committee, visit www.treefrog.fr

Cardiost, Inc. Strengthens Scientific Advisory Board with Renowned Cardiovascular Experts, Advances Prototype Development with OEDIT Grant Support

Retrieved on: 
Vendredi, septembre 29, 2023
Medical device, University, Heart failure, Interventional cardiology, Lung transplantation, HF, Johnson & Johnson, Clinical trial, Coronavirus Scientific Advisory Board, Research, The Journal of Heart and Lung Transplantation, Biomedical engineering, Universidad, PCI, Harvard Medical School, IMACS, University of Los Andes (Colombia), CO, Journal, Wallace H. Coulter Department of Biomedical Engineering, User experience, Mount Sinai Medical Center, Publication, Biomedicine, MD, Montefiore Medical Center, Cardiology, Universidad de los Andes, Internal medicine, Fort Collins, Colorado, Journal of Cardiac Surgery, LVAD, Ventricular assist device, Hospital, MCS, Massachusetts General Hospital, CFD, Pharmaceutical industry, Heart, Patient

Cardiost is currently designing an alpha prototype of its LAUD, or Left Atrium Unloading Device, with money it received from Colorado’s OEDIT grant in early 2023.

Key Points: 
  • Cardiost is currently designing an alpha prototype of its LAUD, or Left Atrium Unloading Device, with money it received from Colorado’s OEDIT grant in early 2023.
  • The LAUD is a durable mechanical circulatory support (MCS) device to treat late-stage patients suffering from heart failure (HF).
  • Cardiost is focused on developing cardiovascular devices medical devices in the cardiovascular space.
  • “We are thrilled to add Dr. Goldstein and Dr. Moreno to our Scientific Advisory Board, both KOLs in their respective fields – MCS the former and PCI the latter.

Iuvo Therapeutics Ltd. and Evergreen Acquisitions Corp. Enter into Definitive Agreement for Reverse Takeover Transaction

Retrieved on: 
Jeudi, avril 14, 2022
SVKM's NMIMS, Consolidation, Audit committee, Research, Sale, Technology, Country, School, Rotman School of Management, Acquisition, University, Business, NEO, University of Los Andes (Colombia), MBA, ISO, Partner, Regulation, Teva Canada, Business school, Institute of Corporate Directors, Pump, GDP, Name change, Projection, Engineering, News, Teva, GMP, Mission statement, Toronto Stock Exchange, Pain management, Amalgamation, Documentation, New York Stock Exchange, Baxter, Retirement, Director, Union, Institute, Security (finance), Management, Evergreen, Primary energy, Issuer

Vancouver, British Columbia--(Newsfile Corp. - April 14, 2022) - Evergreen Acquisitions Corp. ("Evergreen") is pleased to announce that it has entered into a definitive binding amalgamation agreement (the "Amalgamation Agreement") among Evergreen, 1000166629 Ontario Inc. ("Subco"), a wholly-owned subsidiary of Evergreen, and Iuvo Therapeutics Ltd. ("Iuvo"), which, subject to certain conditions and applicable shareholder and regulatory approvals, will result in a reverse takeover of Evergreen by Iuvo (the "Proposed Transaction").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - April 14, 2022) - Evergreen Acquisitions Corp. ("Evergreen") is pleased to announce that it has entered into a definitive binding amalgamation agreement (the "Amalgamation Agreement") among Evergreen, 1000166629 Ontario Inc. ("Subco"), a wholly-owned subsidiary of Evergreen, and Iuvo Therapeutics Ltd. ("Iuvo"), which, subject to certain conditions and applicable shareholder and regulatory approvals, will result in a reverse takeover of Evergreen by Iuvo (the "Proposed Transaction").
  • The resulting issuer from the Proposed Transaction (the "Resulting Issuer") will carry on the business of Iuvo.
  • In connection with the Proposed Transaction, Iuvo plans to complete a brokered private placement of offering of subscription receipts to be led by Beacon Securities Limited, which is subject to negotiation and execution of definitive documentation.
  • There can be no assurance that the Proposed Transaction will be completed as proposed or at all.